Document Detail


18F-FDG PET and PET/CT in the evaluation of cancer treatment response.
MedLine Citation:
PMID:  19139187     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Multimodality imaging, as represented by its greatest exponent, PET/CT, has a firm place in the evaluation of a patient presenting with cancer. With 18F-FDG, PET/CT is rapidly becoming the key investigative tool for the staging and assessment of cancer recurrence. In the last 5 y, PET/CT has also gained widespread acceptance as a key tool used to demonstrate early response to intervention and therapy. In this setting, a major clinical need is being addressed with 18F-FDG PET/CT, because of its inherent ability to demonstrate (before other markers of response) if disease modification has occurred. This review presents available evidence to this effect.
Authors:
Simona Ben-Haim; Peter Ell
Related Documents :
18243447 - Role of tonsillectomy in the search for a squamous cell carcinoma from an unknown prima...
15912427 - Clinical value of combined positron emission tomography/computed tomography imaging in ...
11150767 - 10. positron emission tomography in the presurgical evaluation of patients with resecta...
17275167 - Molecular positron emission tomography and pet/ct imaging in urological malignancies.
6867357 - Hydrocephalus in adults. ultrasound detection through surgically created cranial defects.
14765137 - Noninvasive assessment of the injured human spinal cord by means of functional magnetic...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of nuclear medicine : official publication, Society of Nuclear Medicine     Volume:  50     ISSN:  0161-5505     ISO Abbreviation:  J. Nucl. Med.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-13     Completed Date:  2009-03-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0217410     Medline TA:  J Nucl Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  88-99     Citation Subset:  IM    
Affiliation:
Institute of Nuclear Medicine, University College London, and University College London Hospital, London, United Kingdom. Simona.ben-haim@uclh.nhs.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Fluorodeoxyglucose F18 / diagnostic use*
Humans
Neoplasms / radiography*,  radionuclide imaging*,  therapy
Positron-Emission Tomography / methods*
Tomography, X-Ray Computed / methods*
Treatment Outcome
Chemical
Reg. No./Substance:
63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory pros...
Next Document:  Spatial resolution and sensitivity of the Inveon small-animal PET scanner.